Mereo BioPharma is progressing the promising anti-TIGIT antibody, etigilimab, into Phase Ib/II trials for multiple solid tumour types in Q420 and intends to host an investor webinar focusing on this asset in a similar timeframe. Partnering discussions for setrusumab (osteogenesis imperfecta, OI), are ongoing with options sought to retain certain commercialisation rights. Clinical trials are underway again, with Phase II data for alvelestat in anti-alpha trypsin deficiency (AATD) is expected in H221. Financing options for acumapimod and leflutrozole are also being explored. Although its early stage means its contribution to our rNPV model is currently modest, success with etigilimab would be transformative for the company. Using conservative assumptions our current valuation is 101p/share or $5.06/ADS (fully diluted).
26 Oct 2020
H120 results and corporate review
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
H120 results and corporate review
- Published:
26 Oct 2020 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
8
Mereo BioPharma is progressing the promising anti-TIGIT antibody, etigilimab, into Phase Ib/II trials for multiple solid tumour types in Q420 and intends to host an investor webinar focusing on this asset in a similar timeframe. Partnering discussions for setrusumab (osteogenesis imperfecta, OI), are ongoing with options sought to retain certain commercialisation rights. Clinical trials are underway again, with Phase II data for alvelestat in anti-alpha trypsin deficiency (AATD) is expected in H221. Financing options for acumapimod and leflutrozole are also being explored. Although its early stage means its contribution to our rNPV model is currently modest, success with etigilimab would be transformative for the company. Using conservative assumptions our current valuation is 101p/share or $5.06/ADS (fully diluted).